
|Videos|October 19, 2017
Dr. Hoffman-Censits Discusses Immunotherapy in Bladder Cancer
Author(s)Jean Hoffman-Censits, MD
Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses immunotherapy in bladder cancer.
Advertisement
Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses immunotherapy in bladder cancer.
For patients with metastatic urothelial carcinoma who are platinum refractory, and for those patients who are not candidates for cisplatin, immunotherapy is the current standard of care.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
4
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
5




































































